<DOC>
	<DOCNO>NCT00243009</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , radiation therapy donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine together total-body irradiation work treat patient undergo donor stem cell transplant metastatic kidney cancer remove surgery .</brief_summary>
	<brief_title>Fludarabine Total-Body Irradiation Treating Patients Who Are Undergoing Donor Stem Cell Transplant Metastatic Kidney Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy nonmyeloablative conditioning comprise fludarabine total-body irradiation follow allogeneic hematopoietic stem cell transplantation , term 6-month 12-month response rate , patient unresectable metastatic renal cell carcinoma . OUTLINE : - Nonmyeloablative conditioning regimen : Patients receive fludarabine IV day -4 -2 total-body irradiation ( TBI ) day 0 . - Allogeneic hematopoietic stem cell transplantation ( AHSCT ) : After TBI , patient undergo AHSCT day 0 . - Immunosuppression : Patients receive oral cyclosporine twice daily day -3 56 followed taper day 81 . Patients also receive oral mycophenolate mofetil twice daily day 0-27 ( patient relate donor ) OR three time daily day 0-29 twice daily day 30-149 follow additional tapering day 180 ( patient unrelated donor ) . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma , include 1 follow subtypes : Clear cell Papillary Medullary Metastatic disease Not amenable curative surgery No CNS metastases PATIENT CHARACTERISTICS : Performance status Karnofsky 70100 % Life expectancy More 6 month Hematopoietic Not specify Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 4 time ULN Renal Creatinine clearance &gt; 50 mL/min Cardiovascular LVEF &gt; 35 % No symptomatic congestive heart failure Pulmonary DLCO &gt; 40 % predict OR Total lung capacity FEV_1 &gt; 30 % predict PRIOR CONCURRENT THERAPY : Biologic therapy More 30 day since prior biologic therapy Chemotherapy More 30 day since prior chemotherapy Radiotherapy More 30 day since prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>